Managing the Metabolic Burden: Standard of Care

Managing Familial Partial Lipodystrophy Type 5 (FPLD5) is a lifelong journey focused on “complication management.” Because there is currently no way to fix the underlying CIDEC gene mutation, the goal of your care team is to protect your organs—specifically your heart, liver, and pancreas—from the effects of fat “spilling over” into the wrong places ^[1][2].

The Foundation: Dietary Management

Because your fat cells have a limited “storage tank” capacity, the most critical part of your treatment is managing what you put into the system. Diet is considered the cornerstone of FPLD5 care ^[1].

• Calorie Awareness: Since your body cannot safely store excess energy as fat under the skin, avoiding excess calories helps prevent that energy from being stored in your liver and muscles ^[3]. However, weight loss is not automatically the goal, and carbohydrate quality and overall energy balance also matter.
• Fat Restriction: If your triglycerides (blood fats) are very high, your doctor will likely recommend a low-fat diet. In cases of severe hypertriglyceridemia, this may mean getting as little as 20–30% of your daily calories from fat to prevent the blood from becoming “overloaded” ^[4][5]. This must be individualized to your triglyceride levels and nutritional needs by a qualified dietitian to ensure adequate energy, essential fatty acids, and fat-soluble vitamins, rather than acting as a universal prescription.
• Alcohol Avoidance: Alcohol can significantly spike triglyceride levels and increase the risk of pancreatitis, so it is generally recommended to avoid it entirely if your levels are elevated ^[4].

Medications for Blood Sugar and Insulin

When your body can’t store fat properly, it becomes resistant to insulin, leading to high blood sugar.

• Metformin: This is often the first-line medication used to help your body use insulin more effectively and reduce the amount of sugar your liver produces ^[6][1].
• Insulin: If diabetes becomes severe, you may need supplemental insulin. However, because FPLD5 involves high levels of insulin resistance, very high doses are sometimes required ^[6]. Never stop insulin abruptly without consulting your doctor.
• Newer Options: Medications like GLP-1 receptor agonists (the class containing medications like Ozempic or Wegovy) or SGLT2 inhibitors may be used as adjuncts to help lower HbA1c and triglycerides, though more research is needed specifically for FPLD5 ^[7][8]. These medications carry specific risks. SGLT2 inhibitors can increase the risk of euglycemic ketoacidosis, especially during illness or fasting, and GLP-1 agonists cause appetite suppression and weight loss that may not be appropriate for every patient with partial lipodystrophy.

Managing Blood Fats (Lipids)

To lower the risk of heart disease and pancreatitis, your care team will use a combination of medications:

• Statins: These are primarily used to lower “bad” LDL cholesterol and protect your arteries ^[2].
• Fibrates and Omega-3s: Medications like fenofibrate and prescription-strength fish oil are used specifically to lower triglyceride levels ^[2][6]. Combining statins and fibrates requires careful clinician oversight because certain combinations (like using gemfibrozil) have important interaction risks, including severe muscle damage.

Specialist Option: Metreleptin

Metreleptin is a synthetic version of leptin, a hormone produced by fat cells that tells your brain you have enough energy stored. Because people with lipodystrophy have less “healthy” fat, their leptin levels are often very low (hypoleptinemia) ^[1][9].

• How it Works: Metreleptin can help “signal” the body to stop storing fat in the liver and muscles, often leading to improvements in blood sugar and triglycerides ^[10].
• Approval Status: In the United States, metreleptin is officially FDA-approved only for Generalized Lipodystrophy. However, for patients with Partial Lipodystrophy (like FPLD5) who have severe metabolic issues and very low leptin levels, specialists may consider it as an “off-label” option ^[11][9]. In Europe and Japan, it is approved for both generalized and partial forms ^[12][13]. Evidence specific to CIDEC/FPLD5 is extremely limited, and there is no universal triglyceride or HbA1c cutoff that determines response in partial lipodystrophy. Furthermore, metreleptin has important safety risks, including the development of neutralizing anti-metreleptin antibodies, a lymphoma warning in the U.S. labeling, and a risk of severe hypoglycemia if used alongside insulin, requiring strict specialist monitoring.
• Is it right for you?: This is a complex decision made by a specialist (usually an endocrinologist). It is considered for patients whose triglycerides or HbA1c remains high despite other treatments ^[14].

Care for FPLD5 is multidisciplinary, often involving an endocrinologist, a specialized dietitian, and sometimes a hepatologist (liver specialist) to monitor for fatty liver disease ^[1]. Consistent follow-up is the best tool for preventing long-term complications.